nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproterone acetate—AR—scrotum—urinary bladder cancer	0.0792	0.332	CbGeAlD
Cyproterone acetate—AR—penis—urinary bladder cancer	0.0357	0.15	CbGeAlD
Cyproterone acetate—NR3C1—urine—urinary bladder cancer	0.0172	0.0722	CbGeAlD
Cyproterone acetate—CYP19A1—prostate gland—urinary bladder cancer	0.00964	0.0404	CbGeAlD
Cyproterone acetate—AR—prostate gland—urinary bladder cancer	0.00853	0.0358	CbGeAlD
Cyproterone acetate—AR—seminal vesicle—urinary bladder cancer	0.00722	0.0303	CbGeAlD
Cyproterone acetate—Ethynodiol—ESR1—urinary bladder cancer	0.00686	0.702	CrCbGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDX1—urinary bladder cancer	0.00646	0.0323	CbGpPWpGaD
Cyproterone acetate—AR—epithelium—urinary bladder cancer	0.00627	0.0263	CbGeAlD
Cyproterone acetate—NR3C1—prostate gland—urinary bladder cancer	0.00618	0.0259	CbGeAlD
Cyproterone acetate—AR—smooth muscle tissue—urinary bladder cancer	0.00604	0.0253	CbGeAlD
Cyproterone acetate—AR—renal system—urinary bladder cancer	0.00582	0.0244	CbGeAlD
Cyproterone acetate—AR—urethra—urinary bladder cancer	0.00571	0.024	CbGeAlD
Cyproterone acetate—CYP19A1—female reproductive system—urinary bladder cancer	0.00526	0.0221	CbGeAlD
Cyproterone acetate—NR3C1—seminal vesicle—urinary bladder cancer	0.00523	0.0219	CbGeAlD
Cyproterone acetate—AR—female reproductive system—urinary bladder cancer	0.00466	0.0195	CbGeAlD
Cyproterone acetate—NR3C1—epithelium—urinary bladder cancer	0.00454	0.0191	CbGeAlD
Cyproterone acetate—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00438	0.0184	CbGeAlD
Cyproterone acetate—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00434	0.0217	CbGpPWpGaD
Cyproterone acetate—AR—vagina—urinary bladder cancer	0.00421	0.0177	CbGeAlD
Cyproterone acetate—NR3C1—renal system—urinary bladder cancer	0.00421	0.0177	CbGeAlD
Cyproterone acetate—NR3C1—urethra—urinary bladder cancer	0.00414	0.0174	CbGeAlD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00389	0.0195	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00384	0.0192	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—PHB—urinary bladder cancer	0.00346	0.0173	CbGpPWpGaD
Cyproterone acetate—NR3C1—female reproductive system—urinary bladder cancer	0.00337	0.0142	CbGeAlD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00316	0.0158	CbGpPWpGaD
Cyproterone acetate—CYP19A1—lymph node—urinary bladder cancer	0.00308	0.0129	CbGeAlD
Cyproterone acetate—NR3C1—vagina—urinary bladder cancer	0.00305	0.0128	CbGeAlD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—PHB—urinary bladder cancer	0.00298	0.0149	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.00297	0.0148	CbGpPWpGaD
Cyproterone acetate—Medroxyprogesterone Acetate—ESR1—urinary bladder cancer	0.00292	0.299	CrCbGaD
Cyproterone acetate—AR—Nuclear Receptors—ESR2—urinary bladder cancer	0.00277	0.0139	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Ovarian Infertility Genes—ESR2—urinary bladder cancer	0.00274	0.0137	CbGpPWpGaD
Cyproterone acetate—AR—lymph node—urinary bladder cancer	0.00273	0.0114	CbGeAlD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.0025	0.0125	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00219	0.011	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00215	0.0107	CbGpPWpGaD
Cyproterone acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.00213	0.0106	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00212	0.0106	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Ovarian Infertility Genes—NCOR1—urinary bladder cancer	0.00211	0.0106	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.0021	0.0105	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00204	0.0102	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—NAT1—urinary bladder cancer	0.00204	0.0102	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00201	0.01	CbGpPWpGaD
Cyproterone acetate—NR3C1—lymph node—urinary bladder cancer	0.00197	0.00828	CbGeAlD
Cyproterone acetate—CYP19A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00186	0.0093	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00184	0.00918	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—NCOR1—urinary bladder cancer	0.00181	0.00903	CbGpPWpGaD
Cyproterone acetate—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.0018	0.00901	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—ESR1—urinary bladder cancer	0.00168	0.00841	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00168	0.00838	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Ovarian Infertility Genes—ATM—urinary bladder cancer	0.00168	0.00837	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Ovarian Infertility Genes—CDK4—urinary bladder cancer	0.00167	0.00834	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00166	0.00831	CbGpPWpGaD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00166	0.0083	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00165	0.00826	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—PPARG—urinary bladder cancer	0.00154	0.00767	CbGpPWpGaD
Cyproterone acetate—AR—FOXA1 transcription factor network—ESR1—urinary bladder cancer	0.0015	0.00748	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00133	0.00665	CbGpPWpGaD
Cyproterone acetate—AR—FOXA1 transcription factor network—CREBBP—urinary bladder cancer	0.00131	0.00655	CbGpPWpGaD
Cyproterone acetate—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.00128	0.00638	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.00128	0.00638	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00125	0.00624	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—CREBBP—urinary bladder cancer	0.00124	0.00622	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—RB1—urinary bladder cancer	0.00124	0.00619	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00121	0.00606	CbGpPWpGaD
Cyproterone acetate—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.00121	0.00604	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00117	0.00584	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.00116	0.00582	CbGpPWpGaD
Cyproterone acetate—AR—Nongenotropic Androgen signaling—SRC—urinary bladder cancer	0.00115	0.00574	CbGpPWpGaD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.00114	0.00571	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.00113	0.00565	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CCNE1—urinary bladder cancer	0.00112	0.00558	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—NAT2—urinary bladder cancer	0.00112	0.00557	CbGpPWpGaD
Cyproterone acetate—CYP19A1—FSH signaling pathway—SRC—urinary bladder cancer	0.0011	0.00552	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.0011	0.0055	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—NCOR1—urinary bladder cancer	0.00108	0.00542	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—urinary bladder cancer	0.00104	0.0052	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	0.00102	0.00512	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00101	0.00504	CbGpPWpGaD
Cyproterone acetate—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.000958	0.00479	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000953	0.00476	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000947	0.00473	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.000922	0.00461	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00092	0.0046	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.000918	0.00459	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000896	0.00448	CbGpPWpGaD
Cyproterone acetate—AR—FOXA1 transcription factor network—EP300—urinary bladder cancer	0.000893	0.00446	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000892	0.00446	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.000887	0.00443	CbGpPWpGaD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CDKN2A—urinary bladder cancer	0.000884	0.00442	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	0.000882	0.00441	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000865	0.00432	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.000857	0.00428	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—EP300—urinary bladder cancer	0.000847	0.00423	CbGpPWpGaD
Cyproterone acetate—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.000832	0.00416	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.000832	0.00416	CbGpPWpGaD
Cyproterone acetate—AR—Nongenotropic Androgen signaling—HRAS—urinary bladder cancer	0.000809	0.00404	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—urinary bladder cancer	0.000807	0.00403	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000805	0.00402	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.000783	0.00391	CbGpPWpGaD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.000778	0.00389	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.00077	0.00385	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000762	0.00381	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000748	0.00374	CbGpPWpGaD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CCND1—urinary bladder cancer	0.000747	0.00373	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CREBBP—urinary bladder cancer	0.000747	0.00373	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—RB1—urinary bladder cancer	0.000744	0.00372	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—urinary bladder cancer	0.000712	0.00356	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.0007	0.0035	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.000697	0.00348	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00068	0.0034	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—RHOA—urinary bladder cancer	0.000675	0.00337	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—urinary bladder cancer	0.000646	0.00323	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000644	0.00322	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000611	0.00305	CbGpPWpGaD
Cyproterone acetate—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000608	0.00304	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000606	0.00303	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000605	0.00302	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—urinary bladder cancer	0.000602	0.00301	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000601	0.003	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000599	0.003	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000596	0.00298	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000591	0.00295	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—urinary bladder cancer	0.000584	0.00292	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000584	0.00292	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000576	0.00288	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000568	0.00284	CbGpPWpGaD
Cyproterone acetate—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000567	0.00283	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000563	0.00281	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.00056	0.0028	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.000558	0.00279	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—urinary bladder cancer	0.000554	0.00277	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CCND1—urinary bladder cancer	0.000552	0.00276	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000551	0.00275	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000548	0.00274	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000545	0.00272	CbGpPWpGaD
Cyproterone acetate—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000545	0.00272	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000543	0.00271	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CDKN1A—urinary bladder cancer	0.000534	0.00267	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—PTEN—urinary bladder cancer	0.000533	0.00266	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000528	0.00264	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000521	0.0026	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—EP300—urinary bladder cancer	0.000508	0.00254	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000508	0.00254	CbGpPWpGaD
Cyproterone acetate—Pancreatitis—Epirubicin—urinary bladder cancer	0.000508	0.00092	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000507	0.000919	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000505	0.000915	CcSEcCtD
Cyproterone acetate—Breast disorder—Doxorubicin—urinary bladder cancer	0.000501	0.000908	CcSEcCtD
Cyproterone acetate—Anorexia—Etoposide—urinary bladder cancer	0.000501	0.000907	CcSEcCtD
Cyproterone acetate—Diarrhoea—Thiotepa—urinary bladder cancer	0.0005	0.000907	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000499	0.000905	CcSEcCtD
Cyproterone acetate—Decreased appetite—Cisplatin—urinary bladder cancer	0.000498	0.000903	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000498	0.000903	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000495	0.000897	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—SRC—urinary bladder cancer	0.000494	0.00247	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000493	0.00246	CbGpPWpGaD
Cyproterone acetate—Hypotension—Etoposide—urinary bladder cancer	0.000491	0.000889	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.00049	0.00245	CbGpPWpGaD
Cyproterone acetate—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000489	0.000886	CcSEcCtD
Cyproterone acetate—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000489	0.000886	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000487	0.00243	CbGpPWpGaD
Cyproterone acetate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000486	0.000881	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000485	0.00243	CbGpPWpGaD
Cyproterone acetate—Renal failure—Methotrexate—urinary bladder cancer	0.000485	0.000879	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000484	0.00242	CbGpPWpGaD
Cyproterone acetate—Dizziness—Thiotepa—urinary bladder cancer	0.000483	0.000876	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	0.000483	0.00241	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.000482	0.00241	CbGpPWpGaD
Cyproterone acetate—Urticaria—Fluorouracil—urinary bladder cancer	0.00048	0.000871	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.00048	0.0024	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.00048	0.0024	CbGpPWpGaD
Cyproterone acetate—Asthma—Doxorubicin—urinary bladder cancer	0.000479	0.000868	CcSEcCtD
Cyproterone acetate—Pollakiuria—Epirubicin—urinary bladder cancer	0.000478	0.000867	CcSEcCtD
Cyproterone acetate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000478	0.000866	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000478	0.00239	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000477	0.00238	CbGpPWpGaD
Cyproterone acetate—Sweating—Methotrexate—urinary bladder cancer	0.000473	0.000857	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000473	0.000856	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000472	0.000856	CcSEcCtD
Cyproterone acetate—Weight increased—Epirubicin—urinary bladder cancer	0.000471	0.000854	CcSEcCtD
Cyproterone acetate—Haematuria—Methotrexate—urinary bladder cancer	0.00047	0.000852	CcSEcCtD
Cyproterone acetate—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00047	0.000851	CcSEcCtD
Cyproterone acetate—Weight decreased—Epirubicin—urinary bladder cancer	0.000468	0.000849	CcSEcCtD
Cyproterone acetate—Dyspnoea—Etoposide—urinary bladder cancer	0.000468	0.000849	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000467	0.00234	CbGpPWpGaD
Cyproterone acetate—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000467	0.000846	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000466	0.000845	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000466	0.00233	CbGpPWpGaD
Cyproterone acetate—Vomiting—Thiotepa—urinary bladder cancer	0.000465	0.000843	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000464	0.00232	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000462	0.00231	CbGpPWpGaD
Cyproterone acetate—Rash—Thiotepa—urinary bladder cancer	0.000461	0.000836	CcSEcCtD
Cyproterone acetate—Dermatitis—Thiotepa—urinary bladder cancer	0.000461	0.000835	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.000459	0.00229	CbGpPWpGaD
Cyproterone acetate—Headache—Thiotepa—urinary bladder cancer	0.000458	0.00083	CcSEcCtD
Cyproterone acetate—Decreased appetite—Etoposide—urinary bladder cancer	0.000457	0.000827	CcSEcCtD
Cyproterone acetate—Renal failure—Epirubicin—urinary bladder cancer	0.000454	0.000822	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000453	0.000822	CcSEcCtD
Cyproterone acetate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000453	0.000821	CcSEcCtD
Cyproterone acetate—Fatigue—Etoposide—urinary bladder cancer	0.000453	0.000821	CcSEcCtD
Cyproterone acetate—Jaundice—Epirubicin—urinary bladder cancer	0.00045	0.000815	CcSEcCtD
Cyproterone acetate—Constipation—Etoposide—urinary bladder cancer	0.000449	0.000814	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000446	0.000807	CcSEcCtD
Cyproterone acetate—Haemoglobin—Methotrexate—urinary bladder cancer	0.000445	0.000807	CcSEcCtD
Cyproterone acetate—Haemorrhage—Methotrexate—urinary bladder cancer	0.000443	0.000803	CcSEcCtD
Cyproterone acetate—Hepatitis—Methotrexate—urinary bladder cancer	0.000443	0.000803	CcSEcCtD
Cyproterone acetate—Sweating—Epirubicin—urinary bladder cancer	0.000442	0.000802	CcSEcCtD
Cyproterone acetate—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000442	0.000802	CcSEcCtD
Cyproterone acetate—Asthenia—Gemcitabine—urinary bladder cancer	0.000441	0.0008	CcSEcCtD
Cyproterone acetate—Haematuria—Epirubicin—urinary bladder cancer	0.00044	0.000798	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000437	0.000792	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000437	0.00218	CbGpPWpGaD
Cyproterone acetate—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000437	0.000791	CcSEcCtD
Cyproterone acetate—Weight increased—Doxorubicin—urinary bladder cancer	0.000436	0.00079	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000435	0.00218	CbGpPWpGaD
Cyproterone acetate—Pruritus—Gemcitabine—urinary bladder cancer	0.000435	0.000789	CcSEcCtD
Cyproterone acetate—Nausea—Thiotepa—urinary bladder cancer	0.000434	0.000787	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—EGFR—urinary bladder cancer	0.000433	0.00217	CbGpPWpGaD
Cyproterone acetate—Weight decreased—Doxorubicin—urinary bladder cancer	0.000433	0.000785	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000433	0.00216	CbGpPWpGaD
Cyproterone acetate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000433	0.000784	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000432	0.000783	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000429	0.000778	CcSEcCtD
Cyproterone acetate—Pruritus—Fluorouracil—urinary bladder cancer	0.000428	0.000775	CcSEcCtD
Cyproterone acetate—Visual impairment—Methotrexate—urinary bladder cancer	0.000427	0.000773	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000422	0.000765	CcSEcCtD
Cyproterone acetate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000421	0.000763	CcSEcCtD
Cyproterone acetate—Renal failure—Doxorubicin—urinary bladder cancer	0.00042	0.000761	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000419	0.0021	CbGpPWpGaD
Cyproterone acetate—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000419	0.000759	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000418	0.00209	CbGpPWpGaD
Cyproterone acetate—Urticaria—Etoposide—urinary bladder cancer	0.000417	0.000756	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.000417	0.00208	CbGpPWpGaD
Cyproterone acetate—Haemoglobin—Epirubicin—urinary bladder cancer	0.000416	0.000755	CcSEcCtD
Cyproterone acetate—Jaundice—Doxorubicin—urinary bladder cancer	0.000416	0.000755	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000416	0.00208	CbGpPWpGaD
Cyproterone acetate—Abdominal pain—Etoposide—urinary bladder cancer	0.000415	0.000752	CcSEcCtD
Cyproterone acetate—Body temperature increased—Etoposide—urinary bladder cancer	0.000415	0.000752	CcSEcCtD
Cyproterone acetate—Haemorrhage—Epirubicin—urinary bladder cancer	0.000414	0.000751	CcSEcCtD
Cyproterone acetate—Hepatitis—Epirubicin—urinary bladder cancer	0.000414	0.000751	CcSEcCtD
Cyproterone acetate—Eye disorder—Methotrexate—urinary bladder cancer	0.000414	0.00075	CcSEcCtD
Cyproterone acetate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000414	0.00075	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000413	0.00206	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000412	0.00206	CbGpPWpGaD
Cyproterone acetate—Asthenia—Cisplatin—urinary bladder cancer	0.000411	0.000745	CcSEcCtD
Cyproterone acetate—Sweating—Doxorubicin—urinary bladder cancer	0.000409	0.000742	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000407	0.00204	CbGpPWpGaD
Cyproterone acetate—Haematuria—Doxorubicin—urinary bladder cancer	0.000407	0.000738	CcSEcCtD
Cyproterone acetate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000407	0.000738	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000405	0.00203	CbGpPWpGaD
Cyproterone acetate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000404	0.000732	CcSEcCtD
Cyproterone acetate—Angiopathy—Methotrexate—urinary bladder cancer	0.000402	0.000728	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.0004	0.002	CbGpPWpGaD
Cyproterone acetate—Immune system disorder—Methotrexate—urinary bladder cancer	0.0004	0.000725	CcSEcCtD
Cyproterone acetate—Dizziness—Fluorouracil—urinary bladder cancer	0.0004	0.000725	CcSEcCtD
Cyproterone acetate—Visual impairment—Epirubicin—urinary bladder cancer	0.000399	0.000724	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000399	0.000723	CcSEcCtD
Cyproterone acetate—Chills—Methotrexate—urinary bladder cancer	0.000397	0.00072	CcSEcCtD
Cyproterone acetate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000392	0.000711	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000392	0.00071	CcSEcCtD
Cyproterone acetate—Alopecia—Methotrexate—urinary bladder cancer	0.000391	0.000709	CcSEcCtD
Cyproterone acetate—Vomiting—Gemcitabine—urinary bladder cancer	0.000391	0.000709	CcSEcCtD
Cyproterone acetate—Mental disorder—Methotrexate—urinary bladder cancer	0.000388	0.000703	CcSEcCtD
Cyproterone acetate—Rash—Gemcitabine—urinary bladder cancer	0.000388	0.000703	CcSEcCtD
Cyproterone acetate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000387	0.000702	CcSEcCtD
Cyproterone acetate—Eye disorder—Epirubicin—urinary bladder cancer	0.000387	0.000702	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000387	0.000701	CcSEcCtD
Cyproterone acetate—Malnutrition—Methotrexate—urinary bladder cancer	0.000385	0.000699	CcSEcCtD
Cyproterone acetate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000385	0.000698	CcSEcCtD
Cyproterone acetate—Headache—Gemcitabine—urinary bladder cancer	0.000385	0.000698	CcSEcCtD
Cyproterone acetate—Vomiting—Fluorouracil—urinary bladder cancer	0.000384	0.000697	CcSEcCtD
Cyproterone acetate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000383	0.000695	CcSEcCtD
Cyproterone acetate—Hepatitis—Doxorubicin—urinary bladder cancer	0.000383	0.000695	CcSEcCtD
Cyproterone acetate—Rash—Fluorouracil—urinary bladder cancer	0.000381	0.000691	CcSEcCtD
Cyproterone acetate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000381	0.00069	CcSEcCtD
Cyproterone acetate—Headache—Fluorouracil—urinary bladder cancer	0.000379	0.000687	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000379	0.00189	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000378	0.00189	CbGpPWpGaD
Cyproterone acetate—Asthenia—Etoposide—urinary bladder cancer	0.000377	0.000683	CcSEcCtD
Cyproterone acetate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000377	0.000683	CcSEcCtD
Cyproterone acetate—Angiopathy—Epirubicin—urinary bladder cancer	0.000376	0.000681	CcSEcCtD
Cyproterone acetate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000374	0.000678	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000373	0.000677	CcSEcCtD
Cyproterone acetate—Chills—Epirubicin—urinary bladder cancer	0.000372	0.000674	CcSEcCtD
Cyproterone acetate—Pruritus—Etoposide—urinary bladder cancer	0.000372	0.000673	CcSEcCtD
Cyproterone acetate—Visual impairment—Doxorubicin—urinary bladder cancer	0.000369	0.00067	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—GSTZ1—urinary bladder cancer	0.000367	0.00183	CbGpPWpGaD
Cyproterone acetate—Alopecia—Epirubicin—urinary bladder cancer	0.000366	0.000664	CcSEcCtD
Cyproterone acetate—Nausea—Gemcitabine—urinary bladder cancer	0.000365	0.000662	CcSEcCtD
Cyproterone acetate—Vomiting—Cisplatin—urinary bladder cancer	0.000364	0.000661	CcSEcCtD
Cyproterone acetate—Mental disorder—Epirubicin—urinary bladder cancer	0.000363	0.000658	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000362	0.000657	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000362	0.00181	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000362	0.00181	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000362	0.00181	CbGpPWpGaD
Cyproterone acetate—Rash—Cisplatin—urinary bladder cancer	0.000361	0.000655	CcSEcCtD
Cyproterone acetate—Dermatitis—Cisplatin—urinary bladder cancer	0.000361	0.000654	CcSEcCtD
Cyproterone acetate—Malnutrition—Epirubicin—urinary bladder cancer	0.000361	0.000654	CcSEcCtD
Cyproterone acetate—Diarrhoea—Etoposide—urinary bladder cancer	0.000359	0.000651	CcSEcCtD
Cyproterone acetate—Nausea—Fluorouracil—urinary bladder cancer	0.000359	0.000651	CcSEcCtD
Cyproterone acetate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000358	0.000649	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000358	0.000648	CcSEcCtD
Cyproterone acetate—Anaemia—Methotrexate—urinary bladder cancer	0.000356	0.000646	CcSEcCtD
Cyproterone acetate—Tension—Epirubicin—urinary bladder cancer	0.000354	0.000642	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000349	0.00175	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTO2—urinary bladder cancer	0.000348	0.00174	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—NAT1—urinary bladder cancer	0.000348	0.00174	CbGpPWpGaD
Cyproterone acetate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000348	0.00063	CcSEcCtD
Cyproterone acetate—Malaise—Methotrexate—urinary bladder cancer	0.000348	0.00063	CcSEcCtD
Cyproterone acetate—Dizziness—Etoposide—urinary bladder cancer	0.000347	0.000629	CcSEcCtD
Cyproterone acetate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000346	0.000628	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000346	0.000626	CcSEcCtD
Cyproterone acetate—Leukopenia—Methotrexate—urinary bladder cancer	0.000345	0.000625	CcSEcCtD
Cyproterone acetate—Chills—Doxorubicin—urinary bladder cancer	0.000344	0.000624	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000342	0.00171	CbGpPWpGaD
Cyproterone acetate—Nausea—Cisplatin—urinary bladder cancer	0.00034	0.000617	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000339	0.0017	CbGpPWpGaD
Cyproterone acetate—Alopecia—Doxorubicin—urinary bladder cancer	0.000339	0.000614	CcSEcCtD
Cyproterone acetate—Cough—Methotrexate—urinary bladder cancer	0.000336	0.00061	CcSEcCtD
Cyproterone acetate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000336	0.000609	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000335	0.000607	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000335	0.00167	CbGpPWpGaD
Cyproterone acetate—Vomiting—Etoposide—urinary bladder cancer	0.000334	0.000605	CcSEcCtD
Cyproterone acetate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000334	0.000605	CcSEcCtD
Cyproterone acetate—Anaemia—Epirubicin—urinary bladder cancer	0.000333	0.000604	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000333	0.00166	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000332	0.00166	CbGpPWpGaD
Cyproterone acetate—Agitation—Epirubicin—urinary bladder cancer	0.000331	0.000601	CcSEcCtD
Cyproterone acetate—Rash—Etoposide—urinary bladder cancer	0.000331	0.0006	CcSEcCtD
Cyproterone acetate—Dermatitis—Etoposide—urinary bladder cancer	0.000331	0.0006	CcSEcCtD
Cyproterone acetate—Headache—Etoposide—urinary bladder cancer	0.000329	0.000596	CcSEcCtD
Cyproterone acetate—Tension—Doxorubicin—urinary bladder cancer	0.000328	0.000594	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000326	0.000591	CcSEcCtD
Cyproterone acetate—Malaise—Epirubicin—urinary bladder cancer	0.000325	0.00059	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000325	0.00162	CbGpPWpGaD
Cyproterone acetate—Discomfort—Methotrexate—urinary bladder cancer	0.000324	0.000588	CcSEcCtD
Cyproterone acetate—Syncope—Epirubicin—urinary bladder cancer	0.000323	0.000586	CcSEcCtD
Cyproterone acetate—Leukopenia—Epirubicin—urinary bladder cancer	0.000323	0.000585	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—UGT2B7—urinary bladder cancer	0.000318	0.00159	CbGpPWpGaD
Cyproterone acetate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000317	0.000575	CcSEcCtD
Cyproterone acetate—Cough—Epirubicin—urinary bladder cancer	0.000315	0.00057	CcSEcCtD
Cyproterone acetate—Nausea—Etoposide—urinary bladder cancer	0.000312	0.000565	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000311	0.00156	CbGpPWpGaD
Cyproterone acetate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00031	0.000561	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000308	0.000559	CcSEcCtD
Cyproterone acetate—Anaemia—Doxorubicin—urinary bladder cancer	0.000308	0.000559	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000308	0.000558	CcSEcCtD
Cyproterone acetate—Agitation—Doxorubicin—urinary bladder cancer	0.000307	0.000556	CcSEcCtD
Cyproterone acetate—Skin disorder—Methotrexate—urinary bladder cancer	0.000306	0.000554	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000305	0.000553	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000304	0.000551	CcSEcCtD
Cyproterone acetate—Discomfort—Epirubicin—urinary bladder cancer	0.000303	0.00055	CcSEcCtD
Cyproterone acetate—Malaise—Doxorubicin—urinary bladder cancer	0.000301	0.000546	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000301	0.0015	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.0003	0.0015	CbGpPWpGaD
Cyproterone acetate—Anorexia—Methotrexate—urinary bladder cancer	0.0003	0.000543	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.000299	0.0015	CbGpPWpGaD
Cyproterone acetate—Syncope—Doxorubicin—urinary bladder cancer	0.000299	0.000542	CcSEcCtD
Cyproterone acetate—Leukopenia—Doxorubicin—urinary bladder cancer	0.000299	0.000541	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.000295	0.00147	CbGpPWpGaD
Cyproterone acetate—Oedema—Epirubicin—urinary bladder cancer	0.000294	0.000534	CcSEcCtD
Cyproterone acetate—Hypotension—Methotrexate—urinary bladder cancer	0.000294	0.000533	CcSEcCtD
Cyproterone acetate—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000293	0.000532	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000292	0.00146	CbGpPWpGaD
Cyproterone acetate—Cough—Doxorubicin—urinary bladder cancer	0.000291	0.000528	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.00029	0.00145	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.00029	0.00145	CbGpPWpGaD
Cyproterone acetate—Shock—Epirubicin—urinary bladder cancer	0.00029	0.000525	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000289	0.00145	CbGpPWpGaD
Cyproterone acetate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000289	0.000523	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000288	0.000522	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000287	0.00144	CbGpPWpGaD
Cyproterone acetate—Tachycardia—Epirubicin—urinary bladder cancer	0.000287	0.000521	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000287	0.00143	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	0.000287	0.00143	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000287	0.00143	CbGpPWpGaD
Cyproterone acetate—Skin disorder—Epirubicin—urinary bladder cancer	0.000286	0.000518	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000285	0.000516	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000284	0.00142	CbGpPWpGaD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000282	0.000511	CcSEcCtD
Cyproterone acetate—Discomfort—Doxorubicin—urinary bladder cancer	0.000281	0.000509	CcSEcCtD
Cyproterone acetate—Anorexia—Epirubicin—urinary bladder cancer	0.000281	0.000509	CcSEcCtD
Cyproterone acetate—Dyspnoea—Methotrexate—urinary bladder cancer	0.00028	0.000508	CcSEcCtD
Cyproterone acetate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000277	0.000502	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000276	0.00138	CbGpPWpGaD
Cyproterone acetate—Hypotension—Epirubicin—urinary bladder cancer	0.000275	0.000499	CcSEcCtD
Cyproterone acetate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000273	0.000496	CcSEcCtD
Cyproterone acetate—Oedema—Doxorubicin—urinary bladder cancer	0.000272	0.000494	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000272	0.000492	CcSEcCtD
Cyproterone acetate—Fatigue—Methotrexate—urinary bladder cancer	0.000271	0.000492	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	0.000271	0.00135	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000268	0.00134	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000268	0.00134	CbGpPWpGaD
Cyproterone acetate—Shock—Doxorubicin—urinary bladder cancer	0.000268	0.000486	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000267	0.000484	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000267	0.000483	CcSEcCtD
Cyproterone acetate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000266	0.000482	CcSEcCtD
Cyproterone acetate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000265	0.00048	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	0.000264	0.00132	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000263	0.00132	CbGpPWpGaD
Cyproterone acetate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000263	0.000477	CcSEcCtD
Cyproterone acetate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000262	0.000476	CcSEcCtD
Cyproterone acetate—Anorexia—Doxorubicin—urinary bladder cancer	0.00026	0.000471	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000259	0.00047	CcSEcCtD
Cyproterone acetate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000259	0.00047	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000257	0.000466	CcSEcCtD
Cyproterone acetate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000256	0.000464	CcSEcCtD
Cyproterone acetate—Hypotension—Doxorubicin—urinary bladder cancer	0.000255	0.000461	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000254	0.000461	CcSEcCtD
Cyproterone acetate—Fatigue—Epirubicin—urinary bladder cancer	0.000254	0.00046	CcSEcCtD
Cyproterone acetate—Constipation—Epirubicin—urinary bladder cancer	0.000252	0.000456	CcSEcCtD
Cyproterone acetate—Urticaria—Methotrexate—urinary bladder cancer	0.00025	0.000453	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.00025	0.00125	CbGpPWpGaD
Cyproterone acetate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000249	0.000451	CcSEcCtD
Cyproterone acetate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000249	0.000451	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000246	0.00123	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000244	0.00122	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000243	0.00044	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000243	0.00044	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000241	0.000436	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000241	0.0012	CbGpPWpGaD
Cyproterone acetate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00024	0.000435	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000238	0.00119	CbGpPWpGaD
Cyproterone acetate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000237	0.000429	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000235	0.00118	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000235	0.000426	CcSEcCtD
Cyproterone acetate—Fatigue—Doxorubicin—urinary bladder cancer	0.000235	0.000426	CcSEcCtD
Cyproterone acetate—Urticaria—Epirubicin—urinary bladder cancer	0.000234	0.000424	CcSEcCtD
Cyproterone acetate—Constipation—Doxorubicin—urinary bladder cancer	0.000233	0.000422	CcSEcCtD
Cyproterone acetate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000233	0.000422	CcSEcCtD
Cyproterone acetate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000233	0.000422	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000232	0.00042	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.000231	0.00116	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000231	0.00115	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.00023	0.00115	CbGpPWpGaD
Cyproterone acetate—Asthenia—Methotrexate—urinary bladder cancer	0.000226	0.000409	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000224	0.000407	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000224	0.00112	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000223	0.000404	CcSEcCtD
Cyproterone acetate—Pruritus—Methotrexate—urinary bladder cancer	0.000223	0.000403	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.000222	0.00111	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000222	0.00111	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000217	0.000393	CcSEcCtD
Cyproterone acetate—Urticaria—Doxorubicin—urinary bladder cancer	0.000216	0.000392	CcSEcCtD
Cyproterone acetate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000215	0.00039	CcSEcCtD
Cyproterone acetate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000215	0.00039	CcSEcCtD
Cyproterone acetate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000215	0.00039	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000212	0.00106	CbGpPWpGaD
Cyproterone acetate—Asthenia—Epirubicin—urinary bladder cancer	0.000211	0.000383	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—TYMP—urinary bladder cancer	0.000211	0.00105	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.00021	0.00105	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—SMC1A—urinary bladder cancer	0.000209	0.00105	CbGpPWpGaD
Cyproterone acetate—Pruritus—Epirubicin—urinary bladder cancer	0.000208	0.000377	CcSEcCtD
Cyproterone acetate—Dizziness—Methotrexate—urinary bladder cancer	0.000208	0.000377	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000205	0.00103	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000203	0.00101	CbGpPWpGaD
Cyproterone acetate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000201	0.000365	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000201	0.00101	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000201	0.000364	CcSEcCtD
Cyproterone acetate—Vomiting—Methotrexate—urinary bladder cancer	0.0002	0.000363	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.0002	0.000999	CbGpPWpGaD
Cyproterone acetate—Rash—Methotrexate—urinary bladder cancer	0.000198	0.000359	CcSEcCtD
Cyproterone acetate—Dermatitis—Methotrexate—urinary bladder cancer	0.000198	0.000359	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000198	0.000987	CbGpPWpGaD
Cyproterone acetate—Headache—Methotrexate—urinary bladder cancer	0.000197	0.000357	CcSEcCtD
Cyproterone acetate—Asthenia—Doxorubicin—urinary bladder cancer	0.000195	0.000354	CcSEcCtD
Cyproterone acetate—Dizziness—Epirubicin—urinary bladder cancer	0.000195	0.000353	CcSEcCtD
Cyproterone acetate—Pruritus—Doxorubicin—urinary bladder cancer	0.000193	0.000349	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—NAT2—urinary bladder cancer	0.000191	0.000953	CbGpPWpGaD
Cyproterone acetate—Vomiting—Epirubicin—urinary bladder cancer	0.000187	0.000339	CcSEcCtD
Cyproterone acetate—Nausea—Methotrexate—urinary bladder cancer	0.000187	0.000339	CcSEcCtD
Cyproterone acetate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000186	0.000338	CcSEcCtD
Cyproterone acetate—Rash—Epirubicin—urinary bladder cancer	0.000186	0.000336	CcSEcCtD
Cyproterone acetate—Dermatitis—Epirubicin—urinary bladder cancer	0.000185	0.000336	CcSEcCtD
Cyproterone acetate—Headache—Epirubicin—urinary bladder cancer	0.000184	0.000334	CcSEcCtD
Cyproterone acetate—AR—Gene Expression—ESR2—urinary bladder cancer	0.000182	0.000911	CbGpPWpGaD
Cyproterone acetate—Dizziness—Doxorubicin—urinary bladder cancer	0.00018	0.000326	CcSEcCtD
Cyproterone acetate—Nausea—Epirubicin—urinary bladder cancer	0.000175	0.000317	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000174	0.000871	CbGpPWpGaD
Cyproterone acetate—Vomiting—Doxorubicin—urinary bladder cancer	0.000173	0.000314	CcSEcCtD
Cyproterone acetate—Rash—Doxorubicin—urinary bladder cancer	0.000172	0.000311	CcSEcCtD
Cyproterone acetate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000172	0.000311	CcSEcCtD
Cyproterone acetate—Headache—Doxorubicin—urinary bladder cancer	0.000171	0.000309	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—RRM2—urinary bladder cancer	0.000165	0.000823	CbGpPWpGaD
Cyproterone acetate—Nausea—Doxorubicin—urinary bladder cancer	0.000162	0.000293	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000159	0.000794	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000159	0.000793	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000153	0.000763	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ENO2—urinary bladder cancer	0.000152	0.000762	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	0.000152	0.000762	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000152	0.000757	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	0.000148	0.000739	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000146	0.000728	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—NCOR1—urinary bladder cancer	0.000141	0.000704	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000138	0.000691	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—ERCC2—urinary bladder cancer	0.000132	0.000661	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—NQO1—urinary bladder cancer	0.000123	0.000614	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000119	0.000597	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000119	0.000596	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—ESR1—urinary bladder cancer	0.000111	0.000553	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	0.000107	0.000534	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000104	0.00052	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	0.000103	0.000512	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—PPARG—urinary bladder cancer	0.000101	0.000504	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	0.0001	0.000502	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.92e-05	0.000496	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—CREBBP—urinary bladder cancer	9.69e-05	0.000484	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—TYMS—urinary bladder cancer	9.53e-05	0.000476	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	9.42e-05	0.000471	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	9.42e-05	0.000471	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	9.06e-05	0.000453	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GPX1—urinary bladder cancer	9.02e-05	0.000451	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	8.86e-05	0.000443	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—ESR1—urinary bladder cancer	8.39e-05	0.000419	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	8.32e-05	0.000416	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—PPARG—urinary bladder cancer	7.65e-05	0.000383	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	7.35e-05	0.000367	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PPARG—urinary bladder cancer	6.75e-05	0.000337	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	6.49e-05	0.000324	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—MYC—urinary bladder cancer	5.75e-05	0.000287	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	5.31e-05	0.000265	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTEN—urinary bladder cancer	4.63e-05	0.000231	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—EP300—urinary bladder cancer	4.42e-05	0.000221	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—MYC—urinary bladder cancer	4.36e-05	0.000218	CbGpPWpGaD
